[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glabellar-lines\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glabellar-lines":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100593964",false,"NCT07013279","Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines","A Double-blind, Randomized, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP712 Inj. in Subjects With Moderate to Severe Glabellar Lines","Inclusion Criteria:\n\n\\- Subjects with a facial wrinkle scale (FWS) score of ≥2 (moderate) for glabellar lines at maximum frown in the investigator's on-site assessment at screening\n\nExclusion Criteria:\n\n\\- Subjects with glabellar lines that cannot sufficiently be improved by physical attempts, e.g., glabellar lines not flattened by hand, in the judgment of the investigator",true,"ALL","19 Years","65 Years",{"count":20,"type":21},324,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines",[27],"Glabellar Lines","NOT_YET_RECRUITING","2025-06-02",{"date":31,"type":32},"2025-06-10","ACTUAL",{"date":34,"type":21},"2025-07-15",{"date":36,"type":21},"2026-03-31",{"name":38,"class":39},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",1,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":40},"100531899","NCT06205797","To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)","A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HU-045 Compared to Xeomin® in Adult Patients With Moderate or Severe Glabellar Lines","Inclusion Criteria:\n\n* 19 Years to 65 Years(Adult, Older Adult)\n* 2(Moderate) and\u002For above of Facial Wrinkle Scale (FWS) score at frown in investigator's live assessment.\n* Subject who signed voluntarily in informed consent form and fully understood about this clinical trial.\n\nExclusion Criteria:\n\n* Subject who has history of any diseases following. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)\n* History of bleeding disorder\n* Infection, dermatological condition or scar at the treatment injection sites\n* Subject who has marked facial asymmetry\n* History of facial nerve palsy or eyebrow\u002Feyelid ptosis\n* History of surgical procedures affecting on the lines of forehead and\u002For middle of the forehead areas\n* History of malignant tumor within 5 years (except for basal cell carcinoma\n* Any disease and condition that, in the view of the investigator, would interfere with study participation\n* History of alcohol or drug addiction\n* Subject who has been treated with any botulinum toxin drug within 6 months\n* Persons who have received the following drugs with systemic muscle relaxant action within 4 weeks of screening\n* Subjects taking more than 1,000 IU\u002Fday of anticoagulants, antiplatelet agents, NSAIDs, or vitamin E within 7 days prior to administration of the investigational drug (excluding low-dose aspirin)\n* A person who has received a retinoid series of medications during the following period as of the time of screening\n* Subjects who have hypersensitivity reaction to investigational drug or local anesthetics\n* History of Anaphylaxis or severe combined allergy disease\n* Subject who has physically untreatable glabellar lines like that can't be spread out even if someone forces it to spread out\n* Pregnant and lactating women F- ertile women and men who have plans to pregnancy and who do not agree to appropriate contraception.\n* Participant who has been treated with any investigational drug within 30 days from screening\n* Subject who are not eligible for this study based on investigator's judgement.",{"count":48,"type":21},312,[24],"A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines",[27],"RECRUITING","2024-10-01",{"date":55,"type":32},"2024-10-03",{"date":57,"type":32},"2024-06-20",{"date":59,"type":21},"2025-03-31",{"name":61,"class":39},"Huons Biopharma",""]